Medtronic Stock To Go Ex-dividend Tomorrow (MDT)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Medtronic (NYSE: MDT) is tomorrow, December 13, 2012. Owners of shares as of market close today will be eligible for a dividend of 26 cents per share. At a price of $42.77 as of 2:41 p.m. ET, the dividend yield is 2.4%.

The average volume for Medtronic has been 4.6 million shares per day over the past 30 days. Medtronic has a market cap of $43.08 billion and is part of the health care sector and health services industry. Shares are up 11.3% year to date as of the close of trading on Tuesday.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Medtronic Ratings Report.

See our dividend calendar or top-yielding stocks list.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Medtronic Looks Vulnerable to a Bigger Decline

FDA Approves Abbott Heart Device, Stock Rises

Measure the Meaning of This Rally: Cramer's 'Mad Money' Recap (Tues 8/22/17)

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Cramer: This Rally Isn't Without Meaning